KURA - Earnings call transcript Q3 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, and welcome to the Kura Oncology 3Q Conference Call. Today’s call is being recorded. I'll now turn the call over to Pete De Spain. Please go ahead, sir.

Pete De Spain

Thank you, Paula. to Third welcome Call. XXXX and afternoon, Kura Quarter Oncology's Conference Good

our and us me Dr. Dale, Chief Officer; Officer; are Chief Grasso, are the our Officer, and Chief Operating and available Financial Wilson, Marc Joining to Kirsten call answer Commercial and Chief Troy Medical on Flowers, Dr. Business questions. Chief Officer; our and Officer; President Dr. Kathy with Chief Stephen our Officer our also Executive Ford,

to the over filings to remind today available the now that, call represent Wilson, differ I Oncology CEO call Before website include uncertainties turn SEC, to the which I as refer Wilson, President based and SEC statements Dr. would on factors like Please risks to and of materially risk company. to call expectations. affect concerning that and you Kura over will from the Kura's that of the turn Oncology. involve management's are or with could judgment With for Such Kura Dr. the today's could expected that Troy may results on from cause will forward-looking statements results. I current actual information

Troy Wilson

for Thank expansion cohorts past for pleased for has and synergistic in and its and you, made head in Phase tipifarnib Xb and quarter, studies for the cell alpelisib of enrollment the KO-XXX the combination trial site squamous joining venetoclax; thank X/X plus for activity over neck highlighted progress KO-XXX, IND-enabling potential KO-XXXX. our of mechanisms us carcinoma; Phase first with all molecular clinical data, Pete, this I'm activated ongoing the the afternoon. you by team by highlighting accelerated preclinical in

transferase our next-generation patients, on healthcare carcinomas, to the that tipifarnib our our we inhibitor, and to we And cell deliver providers leukemia, experience, solid believe organization, in farnesyl farnesyl for menin our remain value. programs: transferase an significant these and As and the head squamous programs resources in KO-XXX acute we create We value neck believe KO-XXXX inhibitor, financial main three focused have have shareholders. tumors. potential in and leadership inhibitor,

take Xa cohorts, step is recommended of Phase goal and lower expansion XXX completed comprised refractory with with key We're those KMTXA clinical Xa at study demonstrated look Phase within dose A relapsed tolerability Phase milligrams study. based programs, We've combination. rearrangement. NPMX patients evaluated a currently including KO-XXX of ongoing patients closer showed in and/or KO-XXX. KMTX-rearranged let's of study. mutations a the encouraging refractory in AML, Phase of selected being is no each of of the cohort enrolling beginning the dose, two Xb profile, XXX, activity of AML. The on of which tolerability an with escalation KO-XXX, for the Phase dose each higher clinical activity prolongation. of a Now a in our conduct demonstrated as with all-comer is and dose and/or plan population dose single-agent were the intend QTC and and NPMX relapsed which a and safety a monotherapy milligrams, in favorable the X determination development a notably safety also to both Xb We with and mutant the is evidence comprehensive XXX or progress

patients now XX also profile. in study preliminary enthusiasm global an half evidence Phase for safety and We doses screening actively from far results of enrollment of by our encouraged both with Xb activity the tolerability thus of We're the a and the investigators the by encouraged continue approximately to be study. favorable with estimated sites at

efficacy maintain and X of The safety sites Xb we cohort X aggressively to the to portion enrolling dose. first study selective the registration-directed enrollment recommended and gives us study. X XX assess of our to us This a of quarter of we Phase in by in flexibility guidance of at determine Once Europe study also will to pharmacokinetics portion while each transition recommended patients study cohort and the the protocol Phase to U.S. each subsequent we in patients patients Phase and add anticipation for the in XXXX. cohort. enables Phase enroll tolerability, evaluable in patients the enrolled, XX study, the in continue of into the continue up Phase We Xb the the the dose,

potential the treated recommended believe at have Phase dose, X of study, Xb intend meeting, data our an potential Xa results a to Based Phase the Phase and to the including our to be refine the toward Xb us provide maintaining registration recommended Phase a determination on continue Phase to-date, it and a time first-in-class all study we not the update the population. to Thus, best-in-class to X recommended Phase we helps progress and future preclinical the at a line both dose Phase contribute believe from our and of development data X clinical dose. from of more to path X the enables on comprehensive menin totality inhibitor. Importantly, patients medical pending only KO-XXX start patient for the We aggressive has to us but a selection program. registrational while

some strategy in to builds get monotherapy, KO-XXX As us additional earlier a such, activities. to already lines giving on potential of of flexibility register more as quickly, opportunities Efforts that these we're larger while designing including to therapy. to combination underway development the a support development are

and Dr. data have the progress Bala at with for in ASH encouraging American highlighting potential and website. We with collaboration recommended to on for molecular dose abstract month Kapil accepted available through Meeting. today MD we The in a Anderson, Society models. continue Bala's activity of the Dr. mutant our quarter. Hematology its as to for a KMTX-rearranged with toward AML generated These now published and the look sharing combination earlier of KO-XXX Annual to X upcoming you, mechanisms NPMX research KO-XXX been next drive data forward presentation For next at been Phase synergistic and was presentation preclinical has venetoclax is example,

attention inhibition a now transferase, oncology. continue farnesyl our one transferase potentially therapeutic to to farnesyl as opportunities commercial and franchise, valuable multiple in Turning view we to potential deliver with

earlier today, with lymphoma. example, the For results T-cell a with final patients tipifarnib peripheral in X was study or an abstract of refractory published Phase relapsed from

The development early by Although on X Dr. Phase to Thomas continued presented lymphoma results will be study's tipifarnib and carcinoma T-cell programs neck an cell and continued. hematologist on in the Mayo oral Witzig, Clinic investigator squamous our we XXXX, presentation paused and focus in AML, head and of at at lead survival be in also demonstrated patients to the patients. in with final trial in a transferase the clinical with ASH overall drive website. can the response in patients abstract farnesyl rate The to subtypes median T-cell of certain of overall clinical benefit in benefit target an This ASH. of including XX.X% potential T-cell found angioimmunoblastic lymphoma, underscore XX.X-months lymphoma

metastatic patients therapy year HRAS most which neck X from from was with HNSCC, focused of Journal you carry tipifarnib in upon data or The treatment breakthrough RUN-HN gene. is earlier our effort the has Tipifarnib this cell the and in HNSCC. mutant trial, squamous awarded with As most advanced or designation designation which been of know, based carcinoma, head on with recurrent mutations published patients breakthrough of for Clinical Phase FDA the HRAS was therapy Oncology. our

as on tipifarnib AIM-HN a monotherapy We remain with continue registration-directed trial patients and to of HNSCC. focused be motivated our by HRAS mutant these data in

expansion believe we In larger in subsets. tipifarnib for addition the HRAS to opportunity to of addressing an combinations urgent genetic patients, rational HNSCC a the the and provides unmet mutant need development beachhead to for

combination was carcinomas. farnesyl the the regimens we've potential these rationale of month, a paper kinase journal preclinical published last as tipifarnib potential combination and priority, the clinical inhibitors highlighting the data in review squamous cell transferase PIX a the combinations, for and that self-inhibitor. in Among identified Just and support Cancers, in

significant to clinical We've now indications, the network the activity has are patients cohort combination collaborators, data internal have believe of mutant us in encouraging targeted combination academic as it opportunities current first tipifarnib We're other the identify collaboration PIX-kinase own we're PIX-kinase for The potential in has our opportunities addressable X/X evaluate with begin patients tumor therapies alpelisib site, self and and exciting better to HNSCC. transferase in solid some combination These should provide in of a trial inhibiting of we Phase kinase on combination. patients patients HNSCC. preparing believe and in of with through sequencing, and in now with farnesyl we include patients the can for with which identified relative the represent tipifarnib a is inhibitors we've call large announced has candidate that either development using a Meanwhile, HRAS X to alone. in activated inhibitor our quarter, for with to the tipifarnib. physical with inhibitor HNSCC. and value farnesyl this study that properties nominated preclinical this with with potential allow trial. approved and in next-generation for identified current our end to we program tipifarnib a will actively relative with antitumor transferase initial the recommended HNSCC, which PIX of oncogenes who to as with to lead Novartis in suggests chemical the Alpelisib next-generation a track efforts breast potency the Our by combining dosing to HNSCC to quarter, alpha compound year. creation. we improved activity codependent Phase XX% inhibitor PIKXCA-dependent pharmacokinetic population dose combination as patients total and cancer, be Last of KO-XXXX potential that HNSCC. alpha alpelisib past target tipifarnib the evidence much clinical This demonstrated clinical We patients increase treat meaningfully PIKXCA

and target focus months excited our very rational resistance. Our innovative to With on ahead. delaying in to results. tumor that, the over NextGen financial about to for indications designed large this discussion of a combinations through the drug look a call forward we the biology need sharing with unmet FTI information solid high Marc onset program and I'll more to of is turn address emerging now We're opportunity, of Grasso

Marc Grasso

brief today I in fees a costs the personnel administrative afternoon, $XX.X registration-directed for our increases you, more $XX.X share, related personnel development Net compared the XXXX. third was KO-XXX million General development $XX.X costs, trial the to quarter our for primarily The compensation, and third expenses for compared $XX.X review expenses trial quarter overview million, XXXX share-based detailed G&A for quarter provide $XX.X XXXX for per of $X.XX loss of due per invite quarter the reiterating our our costs to I'll third and expenses primarily in quarter tipifarnib, quarter for were The of to Troy, and full loss year everyone. in good professional share-based you XX-Q activities were Research non-cash R&D of XXXX $X.XX results to with or manufacturing filed the increase for due XXXX. increase XXXX. to the third to third the of a costs and clinical third the million non-cash clinical million $X.X quarter expenses and financial of and XXXX, was compared expenses. of guidance or other in for million our along share of compensation. to Thank was net million a increases XXXX. third for trial to program, related discussion.

September XX, compared million December $XXX.X $XXX.X XXXX. investments of XX, million with of equivalents As short-term XXXX, cash cash, had and of we as

operating for be We continue our the $XXX $XXX million to range the expenses year to in to anticipate XXXX of million. full

and now With cash, range will continue to our turn over to be activities that call fund believe million. XXXX. that, year for I used $XXX our $XXX to current our to continue the plans, Troy. full equivalents in into to the million cash XXXX of net Based we We on operating will the investments to short-term back expect cash in current operations be sufficient

Troy Wilson

Marc. Thanks,

in submit the session, XX into Xb patients lay alpelisib anticipated Phase determine dose cohorts tipifarnib the of quarter complete current first XXXX, that, questions. application me KO-XXX recommended question-and-answer end for of of first quarter and by with enrollment for of dose milestones, the the XXXX. end Phase operator, in XXXX X Phase combination expansion With KOMET-XXX the let we're by the by first now IND the ready of our XXXX, an KO-XXXX Before of to the upcoming X/X the patient evaluable by we in jump out study

Operator

[Operator Leerink. Instructions] Jonathan Chang our We'll take first question with from SVB

Jonathan Chang

for thanks guys, questions. Hi taking my

granular release the on doses both comments you evidence in more a profile? press and and activity can safety color at tolerability indicating favorable of question, First any provide

Troy Wilson

Yes, Jonathan.

we're said, patients and a terms where by are Phase and that encouraged we to point. seeing the clinical at -- this is cohort we're randomized both the the granular more forward we're point, we be given going look we and we As think higher-dose in can't this lower-dose by by activity. But we're Xb providing encouraged qualitative cohort this enrolling that additional that's I direction study as dose, of Unfortunately, any are enrollment, very encouraged to what updates. at

the full quarter we're and to We in determination also remarks said enrollment Phase the dose first on recommended by think, prepared the Jonathan, as XXXX. the that of goals we of track of hit X

Jonathan Chang

Got it. Understood.

thinking show versus latest or levels NPMX activity immune patients? different rearranged KMTXA on KO-XXX or of is your inhibitors question, Second comparable menin whether patients will other in what

Troy Wilson

for realized -- as the a Thanks press your question just pause, continue neglected consistent to favorable with we're what profile we've Sure. last we what point, Phase to the Jonathan, I and in very seen and much very see this safety Xa. let me tolerability that. we've safety question. seen tolerability in characterizing I To answer

that differently. So genetic clinically any I wanted that mention With us those neglected or seen convince subtypes, activity Nothing regard just should two two answer. subtypes. there preclinically, any difference between dose to in for two that had populations any that my would I to last a against basis is respond we those genetic -- believing haven't in actually,

trial and balance. point, very a I you're numbers, looking the there we're at the today this we here think in Xb our have competitors, the on population. can about small At of response believe or that one safety Phase -- we tolerability, X both be whether determine what recommended at activity, our trial skew of the and KMTXA or and small our numbers, we mutant in based the NPMX we sufficient support believe, that dose Phase will -- to the talking

Jonathan Chang

me. review you competitor Understood. thoughts chance love to as your to And from applies any abstracts so, to the you Thank that today? And just get I'd mid-end that question guys it the for if last hear got a Did space. on you. learnings

Troy Wilson

for Yes. Thanks the question.

the I to abstract activity a ASH the one encouraged from our seeing, would continue in by mutant say, populations. seeing very they're KMTXA see did the we we of of in the clinical given encouraging being early. competitors. of data that and it's yes, So be response They're remind in the both that's rate. on CR/CRH gathered bound maturing and They're everybody, perhaps lower seeing we've These real-time. that they're of a XX%. just guidance to rate XX% I'll are the very But

terms isn't least from the X an dose. of believe, We potentially opportunity didn't and continue in in XXX is, to that think I NPMX to Phase abstract at this see both see, register Jonathan, KMTXA. and What clarity didn't that a there's we we criticism recommended

weeks very at we're tolerability as clear and far as and have when the the Phase doing with X picture next determination provide are, That's, ahead. specific perhaps was far going-forward we I clarity were will in right where days that that efficacy they're and as as play agents the as does therapy. of our lines which or they'll data dose. Phase to show in we think, in a on think submitted, much expectation And KO-XXX, or what into where at combination the an ultimate real more we year it color safety read is with very least as the the monotherapy, they missing are full So, found abstract is study and X the that I how when we recommended other earlier through and of a dose. you'll on then registration-enabling that hope And how thing

Jonathan Chang

Thank it. Got you.

Troy Wilson

Sure.

Operator

Moving to Tiago go on, with Credit Suisse. we'll Fauth

Tiago Fauth

those on agents. your on seems how thoughts to CR/CRH, Perhaps question. early get targeted than a just which to wanted provide then data follow-up I for trial. difficult think update. that for But a lower enrollment did on just know taking to on a of in population? metric relapsed/refractory again, some the to for what I achieved the particular quick tipifarnib. be And patient is And it's reasonable interpret They benchmark this your that the context you thanks follow-up Hi, some predict competitors' AIM-HN other specifically?

Just there on any some updates see when helpful. be could data would we

Troy Wilson

Sure.

turn questions in So let's those take Tiago.

for six median of continue hurdle, it's So if response, think we the will, you to on approximately that bar, guide months. duration we the

on of that they you data have to I stress get at days, I the to that that likely It's to of done before, patients stressed duration will data, very but I in study. response get the competitor, right. speak abstract still overly this just from to about optimization, that dose I experience, is and of exercised the from early context Again, all their wouldn't In If you them XX was look to response. our longer. want to Jonathan duration our refer point

So the right I an you deflecting duration encouraging is away, direction. Clearly, I update But to in see think balance, needle the Syndex is It was came the I update. always better. update. was we good a think on think want longer

give you enrollment the enroll not of an that. patients. at That a continues Tiago, around terms In we're update AMHN, point, to to study on

anywhere times remarks, from imminently that's study the sure HRAS part mutant study, than we And which, estimate we in the the very we've X population is PIKXCA be prepared any current pains AMHN why the As X current. of that larger in taken first to in the make dosing indicated by mutant. starting should the we're patients to cannibalize doesn't

And clinical the the on that's thus going seen here ongoing. start for far, will the build I encouraging already is before So data end data think very certainly a tipi to Current that as monotherapy. the year. we've AIM of

Tiago Fauth

the a Thanks it. Got Perfect. lot answers. for

Troy Wilson

Sure.

Operator

with go Lawson we'll Peter next, Barclays. to And

Peter Lawson

taking out of for and questions. how X just the enrollment about I how comes dose, to much Thanks Hey. data when we see think year, we about should we kind Troy? guess, and data expect next recommended think as Phase that should that

Troy Wilson

Yes.

a question, Peter. it's So good

we've is to fact, goal be least -- then patients able the is is and those one requirement as to at to two enroll cohort, the Xb indicated, XX another. evaluable each as far concerned, in to in compare Phase As to the cohorts

Phase evaluable least from you'll XX patients. So Xb, have at the

those Now patients a be early think very either that's But KMTXA they'll as on, in some Xb be because may as later meaningful patients, those Phase will all be enrollment. NPMX. of unlike far Xa, the the or relatively I And update those concerned. is good

In terms a expectation probably of that meeting midyear. where are, present those to is medical our patients data at

you'll help we to six timing. expected, the a and to So maturity study, quantum to we depending longer, what they've tracking from when anywhere of the calibrate to come and good three from Xb some And is on can would course. months enrollment the Peter, from data of tell, just kind the have have we're on on everything

feeling think next about So, we're delivering good I on those milestones quarter.

Peter Lawson

when that you combination Thank X start you. trials. what dose, And to then, development, broaden Perfect. start thinking recommended is plan hit and the just Phase you the running

running there, just or ISTs? it process What's that the Or, is start plan? your them Just yourselves? is you partnerships

Troy Wilson

Yes.

could in opportunity a good We be So see that that's and definitely discussion. -- probably longer frontline. question, much an that's a

Phase there those to as as Peter, we see again, the into genetic can are aware, like the the several care, we'd of X of aggressively provided, We'd standards as patients. on earlier you're both supports an that the setting. to, also depending And it, We of populations. go like dose recommended relapse makeup opportunity in

Phase it's control of certain on the to There of tactically, In everything terms for maintain a that, the clearly will what trial getting do recommended scenes. opportunities you maintain of operational of we design strategically important and of trials. of dose. us the that That's we've working X we been control part ISTs, of is behind on the that but predicated be how execution

to work can the into doing we the will absolute we're submissions Phase to So and greatest the soon the preclinical We that a have move with recommended studies. as preparatory as work combinations, support both urgency. those Phase the the support X and X begin combination the we work, will dose combinations

Peter Lawson

Okay. Thanks much. so

Troy Wilson

Pleasure.

Operator

with And Securities. next, go JMP we'll Benjamin Ren to

Ren Benjamin

or Hey, or guys. about we I think starting that of able you good metrics point you KO-XXX, be questions. any you you study to a terms that Troy, afternoon, and have -- our in registrational throw when a to want path forward. at before way the make of might any for hurdles taking guess, Thanks of go/no-go the decision what a sort commitment do meet just to sort internally off,

Troy Wilson

Ren, for question. Yes, thanks the

a XX you cohorts, to would criteria. to go/no-go XX% have would of are, we've XX% trial that's level sufficient. what don't statistical patient will I to get you power. you're not they do to see think are a powered articulated CR/CRH certainly give they we going So of But enough so properly be but that CR/CRH. These endpoint want confidence its hit obviously

to way I anyone. surprise that's of think great the And any about don't think that's those so to go/no-gos. And

Ren Benjamin

and future. Got what you can strategy, combinations are mean, take you thinking also But the broader only is us else it. not a you a combination that? go sort just about And in where the I like do want a monotherapy strategy through thinking when then of seems maybe to we're as combination, but as other natural it venetoclax And explore? about? developmental

Troy Wilson

would earlier the we is differentiated one the in the Yes. just the ways depend Thanks hoping ability or it. you to is no of is tolerability seen particularly the and either I develop and well-tolerated emphasize, the expecting have toxicities incidence the about drug that, When to one a combine to XXX, that of in compound. tolerability at in call we subtypes. when limit we're efficacy is think I There it and to better very, all for should want very consistent, We've profile, superior competition about pancreatitis. a back -- we've the on And it think safety our combinations combine. was and safety that. made the to additional the which of genetic Really, in And equivalent ability combinations, think comment Xa from no seen evidence Ren.

the in then patients the patients you're unfit, azacitidine you you and you population plus the front work seven which who are inhibitors, in. in have who have on because venetoclax So and to you figure are are depending fit in out line, the have different there principally FLTX three how algorithms patient with

to As failed earlier patient the you of you that one relapse, populations are move look those at have patients who options. frontline

You like may see [indiscernible]. things

work, genetic see And FLTX combinations. these out as different move as may get possible of You many market. to the slotted subtypes, as then we're patients can up how and into arms take efficiently doing to but as possible cover you're Ideally, sort again trials of as you're as where setting to different different able also lot just possible combinations. a they to get much or with Ren, figure you landscape

value going And drive to scenes if doing we're move of work you and do do for we're patients vest that. highly I think All opportunities for field. of on. this just as everybody, of those of behind as into with But the moving, combinations. And think, super the value, lines is want keeping to to close competitive both to you the Obviously, likely want registration a recognizes need you much because lot is monotherapy. therapy. the moving work that And greatest clinically that urgency earlier there commercially, as lot are and a it's best of a possible to I the to a

hope I So color. gives you a bit that little more

Ren Benjamin

great. last That's question me. for One Yep.

really X.X Phase median as AITL, me. well you I forward? put of the final and do just partner either as, context me if these months the in wondering, or potentially to the study revive maybe survival potentially was looks TIPI to Regarding can program program And cause results going that X overall for you that impressive

Troy Wilson

you Yes. that. Great question, and thank for

super they're Yale, are both about Foss, forward. in in thought And we're it, who's lot interesting and to is Dr. thing requirement very the for AITL about by this leaders, Dr. a because high I isn't the mean of you, of So a I rate is the and Dr. were PI. we activity at survival. Witzig impressed a both excited level of be like overall data. companion AITL, response Ren, done. really The more the two Witzig there the think looking there's diagnostic. work

bit So work meet with some T-cell that we're guidance. get we're that's And steps on we And something to to doing We on need think for are to the KOLs. some what internally. lymphoma next indication. the the what's this back going an what really you is ultra-orphan larger. next-gen And we program. do indications. FTI I and high-class neck, make the to regulatory solid PTCL AITL to next the program we're But we're what our to want is the what versus to view doing obviously, what, problem. come are color months that But a for program, little sure to this We with next understand steps AML, doing is the need be hearing, as as head in activity, tipifarnib. we'll be you're meaningful planning able in we diligence opportunity due with a understand and with for large doing if in far we're more this tumor doing any, as

Ren Benjamin

taking Thanks questions, the Perfect. for guys.

Troy Wilson

Sure.

Operator

H.C. And to Joe with Wainwright. next, we'll Pantginis go

Joe Pantginis

question. to Hey on guys, corporate questions wanted have been I Thanks Most focus but taking my question. the answered, good afternoon. of for

with obviously studies. are current very So, you guys busy

supply anticipate studies at had the depth You're the to world to start to here, or additional your for of in and question going chain a well, way. any right global about Have on so lot as you I'll activities? any this issues looking due that way pose now is the

Troy Wilson

the longer The answer short challenges short is activation. answer Yes, The team system. a still are clinical mean, supply, question. have a we There in impacted. been is well, site at is Joe, clinical that's the strong very we no. good answer looks haven't cross-functional operations, I that

kind far still of in drugs to Some supply an of -- generally take as don't now the that we're orally because development the clinical an we we seen that the the KOMET sites outlier. But really small We're just molecule chain have are digesting pandemic. appears It given that study, basis. terms on outpatient of much that impact from be know fallout study. on fortunate unable studies they're activities haven't as Current I we're and an can available if new

works around the point, I any, think advantage. either if to this it. pandemic at little, actually relatively that from So our or chain impact challenges supply But there's the

Joe Pantginis

Thanks, hear. to Great Troy.

Troy Wilson

Pleasure.

Operator

go Cowen. we'll to Previtera Eva on, moving And with

Eva Previtera

thank is taking them trials? questions. just your a transplant? to quick my when response they receive been duration you in counted for addressed, on so censored many patients of Hi, of Luckily, How one. Are go a have

Troy Wilson

for the question. thanks Eva, Yes.

me invite here Stephen, transplant. of respect on response Stephen do phone to your how about particularly who's is to actually answer me you the with Dr. question? want question Let take to Dale, duration Eva’s measured, with

Stephen Dale

Troy. you, Eva, Yes. Thank for Hi, thanks sure. Yes, question. the

transplant. transplant So confounded agent. active if in they’re are until of then very not, of tracking that then censored the censored. distinguish simple to you data point become duration always up the because who terms, data point at in and so the The responds between transplant, patient patients can't response They're because going

So yes, point. data are that censored the at answer is

Eva Previtera

Great. Thank so much. you

Stephen Dale

Thank Eva. you,

Operator

or call the turn to Wilson Troy like I'd now additional any to comments. And back for closing

Troy Wilson

evening, have Look We'll additional have many free In Conference in myself. Virtual Suisse you if thank to forward be questions, the meantime, Thank Paula, again, and or speaking week. Credit joining all, next any you Thanks Great. to participating our then. Marc a feel of contact Pete, the everyone. for good again, you, you Healthcare and please call. with

Operator

Thank your would like to call. you. conclude everyone for And participation. today’s thank that does We

disconnect. now may You

Kura Oncology (KURA) 7 Nov 212021 Q3 Earnings call transcript